AstraZeneca's Brilinta approved in the US to reduce risk of stroke
6th Nov 2020 08:07
(Sharecast News) - AstraZeneca said on Friday that its Brilinta drug has been approved in the US to reduce the risk of stroke.
Read moreAstraZeneca on track to meet guidance
5th Nov 2020 07:10
(Sharecast News) - AstraZeneca said it was on track to meet full-year guidance as the drugs company reported slowing revenue growth in the third quarter.
Read moreThursday preview: Bank of England, AstraZeneca in focus
4th Nov 2020 14:45
(Sharecast News) - The focus on Thursday will shift to the Bank of England, which is expected to boost the size of its asset purchase facility by £110bn, followed later in the session by the US Federal Reserve which may also signal that further quantitative easing is in the pipeline.
Read moreDoctors in England on alert for possible Covid-19 vaccine before Christmas
4th Nov 2020 11:29
(Sharecast News) - Doctors in England have been placed on alert for the potential roll-out of a Covid-19 vaccine this side of Christmas.
Read moreAstraZeneca Covid-19 vaccine to be widely distributed by end Q1 2021 - report
2nd Nov 2020 12:32
(Sharecast News) - The Covid-19 vaccine being developed by AstraZeneca and Oxford University could be in advanced stage of distribution by the end of the first quarter of 2021.
Read morePfizer, AstraZeneca Covid-19 vaccine reviews accelerated - report
30th Oct 2020 11:46
(Sharecast News) - Britain's drug regulator has reportedly started an accelerated reviews of Covid-19 vaccines under development from Pfizer and AstraZeneca.
Read moreAstraZeneca sells Atacand rights to Cheplapharm for $400m
30th Oct 2020 07:23
(Sharecast News) - AstraZeneca said it was selling the commercial rights to its heart failure and hypertension drug Atacand and Atacand Plus in around 70 countries globally to Cheplapharm Arzneimittel for $400m.
Read moreAstraZeneca makes regulatory progress with Enhertu and Forxiga
28th Oct 2020 07:35
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo, said on Wednesday that 'Enhertu', or trastuzumab deruxtecan, has been accepted by the FDA for its supplemental biologics license application (sBLA).
Read moreOxford Covid-19 vaccine produces immune response across all ages - AstraZeneca
26th Oct 2020 09:25
(Sharecast News) - AstraZeneca said on Monday that the Covid-10 vaccine that is being developed by the University of Oxford triggers a similar immune response in people across different age groups, including the elderly.
Read moreAstraZeneca Covid-19 vaccine clinical trial readout may arrive in mid-November, Jefferies says
23rd Oct 2020 11:12
(Sharecast News) - Analysts at Jefferies estimated that an initial read-out on AstraZeneca and Oxford University's ongoing late-stage trial of its Covid-19 vaccine might ready towards the middle of November.
Read moreModerna's Covid-19 vaccine may be ready for use by December
20th Oct 2020 14:01
(Sharecast News) - Moderna's Covid-19 vaccine candidate could be ready for use in December, the company's boss said.
Read moreAstraZeneca gets FDA nod for Tagrisso in certain lung cancers
20th Oct 2020 08:12
(Sharecast News) - AstraZeneca announced on Tuesday that 'Tagrisso', or osimertinib, has received acceptance for its supplemental New Drug Application (sNDA), and has also been granted Priority Review in the United States, for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), after complete tumour resection with curative intent.
Read moreMonday broker round-up
19th Oct 2020 13:30
(Sharecast News) - Intercontinental Hotels Group: Peel Hunt downgrades to hold with a target price of 4,300p.
Read moreAstraZeneca COPD drug wins EU marketing approval
19th Oct 2020 07:02
(Sharecast News) - AstraZeneca said its Trixeo Aerosphere had been given marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Read moreAstraZeneca advances Covid-19 antibodies with US funding
12th Oct 2020 07:29
(Sharecast News) - AstraZeneca announced on Monday that its long-acting antibody (LAAB) combination for Covid-19, AZD7442, would advance into two phase 3 clinical trials in more than 6,000 participants both in and outside the US in the coming weeks.
Read more